HSPA8 globally modulates transcriptome profile and PI3K/AKT signaling pathway to facilitate malignant progression phenotypes of triple-negative breast cancer
An important pro-oncogenic role of HSPA8 is highlighted in TNBC progression, mediated in part through transcriptomic remodeling and activation of the PI3K/AKT signaling pathway.
Abstract
Objective Triple-negative breast cancer (TNBC) represents the most aggressive subtype of breast cancer. HSPA8 is a chaperone protein involved in the proper folding or degradation of many proteins that are implicated in various types of cancers, while its role in TNBC remains unclear. Methods In this study, we extensively explored the cellular function and molecular targets of HSPA8 in TNBC cells by performing small interfering RNA (siRNA)-mediated knockdown, followed by cytological assays and transcriptome sequencing (RNA-seq). Results The results of HSPA8 expression levels across distinct breast cancer subtypes indicated that TNBC exhibits higher HSPA8 expression. Then, cytological experiments demonstrated that knockdown of HSPA8 significantly inhibited TNBC cell proliferation, invasion and migration, and induced apoptosis. Mechanistically, RNA-seq showed that HSPA8 globally regulates gene expression and alternative splicing (AS), particularly modulating expression of genes in PI3K/AKT signaling pathway, and AS of genes in protein phosphorylation. Finally, we experimentally confirmed that knockdown of HSPA8 significantly suppressed the activation of the PI3K/AKT axis and AKT phosphorylation in TNBC cells. Conclusions Our findings highlight an important pro-oncogenic role of HSPA8 in TNBC progression, mediated in part through transcriptomic remodeling and activation of the PI3K/AKT signaling pathway. These results may inform the development of novel targets and strategies for future targeted therapy in TNBC.
GPR19 functions as a novel oncogenic driver and clinically relevant biomarker in breast cancer, particularly in TP53-mutant and TNBC subsets, and was significantly upregulated in TP53-mutant breast cancer, primary tumors, and especially TNBC.
Jihan Qiu, Cheng Tian, Hanzhi Li et al.· Frontiers in Bioscience· 0 citations
It is suggested that TP53AIP1 may serve as a potential prognostic biomarker and tumor-suppressive candidate in breast cancer, with its effects at least partly associated with MAPK pathway attenuation.
Meihai Deng, Xueting Wu, J. Bai et al.· Discover Oncology· 0 citations
Results indicate that TBX6 is aberrantly reactivated in CRC and promotes tumor progression through transcriptional network remodeling, suggesting that TBX6 may represent a potential prognostic biomarker and therapeutic target.
Nianjie Zhang, Leiting Wan, N. He et al.· Gene· 0 citations
It is discovered that STXBP1 regulates global gene expression and alternative splicing profiles in MDA-MB-231 cells by modulating 111 differentially expressed genes and 1,161 regulated alternative splicing events.
GNG12 was found to be broadly downregulated in TNBC and associated with suppression of malignant cellular phenotypes; however, its clinical significance and mechanistic relationship with PI3K/AKT signaling require further validation in larger cohorts and additional experimental models.
Biao-Feng Shan, Le Zhao, Tao Hu et al.· Scientific Reports· 0 citations
A novel EFO2/USF1/SLC2A1 signaling axis that modulates glycolytic metabolism and CD8⁺T cell cytotoxicity is identified, positioning EFO2 as a promising therapeutic target for TNBC treatment.
Lin Jia, Liru Li, Junning Peng et al.· Biochemical Pharmacology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.